Open an account

Northwest Biotherapeutics

NWBO · OTC

$0.1645+$0.0094 (+6.06%)TodayMarket closed ·
Prev close $0.1551

About NWBO

Northwest Biotherapeutics, Inc. is a biotechnology company, which engages in the development of personalized immune therapies for cancer. The company is headquartered in Bethesda, Maryland and currently employs 105 full-time employees. The company went IPO on 2001-12-14. The firm is focused on developing personalized immune therapies for cancer. The company has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The firm's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. The company has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, Northwest Biotherapeutics Capital Limited, Northwest Biotherapeutics B.V., Advent BioServices Ltd., and others.

Employees
105
Headquarters
Bethesda, Maryland
Listed
Dec 14, 2001
Sector
Health Care
Industry
Biotechnology
Website
nwbio.com

NWBO key statistics

Market cap
280.58M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
5.19M
Volume
5.90M
Open price
$0.1589
High today
$0.168
Low today
$0.15
52 Week high
$0.3389
52 Week low
$0.1381

Northwest Biotherapeutics (NWBO) at a glance

As of Oct 20, 2026, Northwest Biotherapeutics (NWBO) shares are priced at $0.1645, giving the company a market cap of 280.58M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.15 and $0.168. The current price is 9.7% above the day's low and 2.1% below its high.

Volume so far is 5.90M shares, in line with the average of 5.19M shares a day.

Over the past year Northwest Biotherapeutics has ranged from $0.1381 to $0.3389, and now sits 13% of the way up that range.

Northwest Biotherapeutics met or beat analyst EPS estimates in 4 of the last 7 quarters. In Q4 FY25 it reported $0.00 per share against an estimate of $0.00.

NWBO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 7 quarters, by 23.4% on average.

  1. Q3 FY02: reported -$50.40 per share against an estimate of -$57.53
  2. Q4 FY02: reported -$24.00 per share against an estimate of -$51.41
  3. Q3 FY13: reported -$0.65 per share against an estimate of -$0.3315
  4. Q4 FY13: reported -$0.40 per share against an estimate of -$0.4182
  5. Q1 FY14: reported -$0.88 per share against an estimate of -$0.3978
  6. Q4 FY24: reported -$0.02 per share against an estimate of $0.00
  7. Q4 FY25: reported $0.00 per share against an estimate of $0.00

NWBO news

  • Press releasePRNewswire

    Northwest Biotherapeutics and the UK National Health Service Blood and Transplant Announce Collaboration to Support DCVax®-L Production

  • Press releasePRNewswire

    Northwest Biotherapeutics Announces Keynote Presentation on Harnessing Immunity: A Personalized, Multi-Target Approach to Cancer At the UK National Health Service Annual Oncology Conference

  • Press releasePRNewswire

    Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company

  • Press releasePRNewswire

    Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses

  • Press releasePRNewswire

    Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting

  • Press releaseGlobe Newswire

    How Advanced Drug Delivery Could Improve Existing Cancer Treatments

  • Press releaseGlobe Newswire

    CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities

  • Press releasePRNewswire

    Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform

Similar companies

Companies in the same industry as Northwest Biotherapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.